For instance, TLK1 inhibition chemosensitizes PCa (PC3) and breast cancer (MDA-MB-231 and 4T1) cells to doxorubicin (Ronald et al. [44]; Jin et al. [45]), glioblastoma cells (U87MG) to temozolomide (Ibrahim et al. [46]), cholangiocarcinoma (SSP25 and HuCCT1) and ovarian cancer cells (SKOV-3) to cisplatin (Takayama et al. [47]; Rho et al. [48]). The gene discussed is TLK1; the disease is posterior cortical atrophy.